These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33894637)

  • 1. Development of new combination anti-leishmanial complexes: Triphenyl Sb(V) mono-hydroxy mono-quinolinolates.
    Duffin RN; Blair VL; Kedzierski L; Andrews PC
    J Inorg Biochem; 2021 Jun; 219():111385. PubMed ID: 33894637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative stability, toxicity and anti-leishmanial activity of triphenyl antimony(v) and bismuth(v) α-hydroxy carboxylato complexes.
    Duffin RN; Blair VL; Kedzierski L; Andrews PC
    Dalton Trans; 2018 Jan; 47(3):971-980. PubMed ID: 29260831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-leishmanial activity of heteroleptic organometallic Sb(v) compounds.
    Ali MI; Rauf MK; Badshah A; Kumar I; Forsyth CM; Junk PC; Kedzierski L; Andrews PC
    Dalton Trans; 2013 Dec; 42(48):16733-41. PubMed ID: 24077559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative stability, cytotoxicity and anti-leishmanial activity of analogous organometallic Sb(V) and Bi(V) acetato complexes: Sb confirms potential while Bi fails the test.
    Duffin RN; Blair VL; Kedzierski L; Andrews PC
    J Inorg Biochem; 2018 Dec; 189():151-162. PubMed ID: 30267965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkyl gallium(III) quinolinolates: A new class of highly selective anti-leishmanial agents.
    Duffin RN; Blair VL; Kedzierski L; Andrews PC
    Eur J Med Chem; 2020 Jan; 186():111895. PubMed ID: 31771825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating aryl substitution: Does it play a role in the anti-leishmanial activity of a series of tetra-aryl Sb(V) fluorinated carboxylates?
    Artem'eva EV; Duffin RN; Munuganti S; Efremov AN; Andrews PC; Sharutina OK; Sharutin VV
    J Inorg Biochem; 2022 Sep; 234():111864. PubMed ID: 35636013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and toxicity of tris-tolyl bismuth(V) dicarboxylates and their biological activity towards Leishmania major.
    Ong YC; Blair VL; Kedzierski L; Tuck KL; Andrews PC
    Dalton Trans; 2015 Nov; 44(41):18215-26. PubMed ID: 26425978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-leishmanial activity and cytotoxicity of a series of tris-aryl Sb(V) mandelate cyclometallate complexes.
    Duffin RN; Blair VL; Kedzierski L; Andrews PC
    J Inorg Biochem; 2020 Feb; 203():110932. PubMed ID: 31790875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antimony(iii) hydroxamic acid complexes as potential anti-leishmanial agents.
    Keogan DM; Oliveira SSC; Sangenito LS; Branquinha MH; Jagoo RD; Twamley B; Santos ALS; Griffith DM
    Dalton Trans; 2018 May; 47(21):7245-7255. PubMed ID: 29757339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The thiol-based reduction of Bi(V) and Sb(V) anti-leishmanial complexes.
    Duffin RN; Stephens LJ; Blair VL; Kedzierski L; Andrews PC
    J Inorg Biochem; 2021 Aug; 221():111470. PubMed ID: 33971522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
    Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR
    Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation on the pharmacological profile of antimony(III) complexes with hydroxyquinoline derivatives: anti-trypanosomal activity and cytotoxicity against human leukemia cell lines.
    Reis DC; Pinto MC; Souza-Fagundes EM; Rocha LF; Pereira VR; Melo CM; Beraldo H
    Biometals; 2011 Aug; 24(4):595-601. PubMed ID: 21221718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.
    Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM
    J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites.
    Lizarazo-Jaimes EH; Reis PG; Bezerra FM; Rodrigues BL; Monte-Neto RL; Melo MN; Frézard F; Demicheli C
    J Inorg Biochem; 2014 Mar; 132():30-6. PubMed ID: 24412095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural diversity in supramolecular complexes of MCl(3) (M = As, Sb, Bi) with constrained thio- and seleno-ether ligands.
    Levason W; Maheshwari S; Ratnani R; Reid G; Webster M; Zhang W
    Inorg Chem; 2010 Oct; 49(19):9036-48. PubMed ID: 20812749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
    Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
    Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability and toxicity of heteroleptic organometallic Bi(V) complexes towards Leishmania major.
    Ong YC; Blair VL; Kedzierski L; Andrews PC
    Dalton Trans; 2014 Sep; 43(34):12904-16. PubMed ID: 25019320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, structural characterization, and biological studies of new antimony(III) complexes with thiones. The influence of the solvent on the geometry of the complexes.
    Ozturk II; Hadjikakou SK; Hadjiliadis N; Kourkoumelis N; Kubicki M; Baril M; Butler IS; Balzarini J
    Inorg Chem; 2007 Oct; 46(21):8652-61. PubMed ID: 17850141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Leishmanial activity of homo- and heteroleptic bismuth(III) carboxylates.
    Andrews PC; Frank R; Junk PC; Kedzierski L; Kumar I; MacLellan JG
    J Inorg Biochem; 2011 Mar; 105(3):454-61. PubMed ID: 20851471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.